ERD

VITAL | Vaccines and Infectious Diseases in the Ageing PopuLation

01-01-2019

-

31-12-2024

Show more information

Organisation SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG

Thera4Care | THERANOSTICS ECOSYSTEM FOR PERSONALISED CARE

01-10-2024

-

30-09-2029

Show more information

Organisation SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG

REMEDI4ALL | BUILDING A SUSTAINABLE EUROPEAN INNOVATION PLATFORM TO ENHANCE THE REPURPOSING OF MEDICINES FOR ALL

01-09-2022

-

31-08-2027

Show more information

Organisation SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG

CATALYSE | Catalysing scientific innovation into food safety action

01-01-2024

-

31-12-2026

Show more information

Organisation SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG

Invest4Health | Mobilising novel finance models for health promotion and disease prevention

01-01-2023

-

30-06-2026

Show more information

Organisation SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG

HTx | Next Generation Health Technology Assessment to support patient-centred, societally oriented, real-time decision-making on access and reimbursement for health technologies throughout Europe

01-01-2019

-

30-06-2024

Show more information

Organisation SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG

SUSTAIN-HTA | Support Utilisation of Sustainable and TAilored INnovative methods for HTA

01-01-2024

-

31-12-2027

Show more information

Organisation SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG

FoodDataQuest | On a Quest for Data-Driven Innovations to fuel Sustainable Food Systems

01-02-2024

-

31-07-2027

Show more information

Organisation SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG

TRUSTING | A TRUSTworthy speech-based AI monitorING system for the prediction of relapse in individuals with schizophrenia

01-07-2023

-

31-12-2028

Show more information

Organisation SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG

SELFIE | Sustainable intEgrated care modeLs for multi-morbidity: delivery, FInancing and performancE

01-09-2015

-

31-08-2019

Show more information

Organisation SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG

IMMUTOL | ADVANCED ANTIGEN-SPECIFIC DENDRITIC CELL-BASED THERAPY TO RE-ESTABLISH TOLERANCE IN IMMUNE-MEDIATED DISEASES

01-05-2023

-

30-04-2027

Show more information

Organisation SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG

EU-TOPIA-EAST | TOwards imProved screening for breast, cervical and colorectal cancer in Eastern-Europe: Equitable, Actionable, Sustainable and Trustworthy

01-05-2021

-

30-04-2026

Show more information

Organisation SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG

HEcoPerMed | Healthcare- and pharma-economic models in support of the International Consortium for Personalised Medicine

01-01-2019

-

30-06-2022

Show more information

Organisation SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG

EU-TOPIA | EU-TOPIA: TOWARDS IMPROVED SCREENING FOR BREAST, CERVICAL AND COLORECTAL CANCER IN ALL OF EUROPE

01-09-2015

-

31-08-2020

Show more information

Organisation SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG

STREXIT2 | A PRAGMATIC CLINICAL STUDY OF NEOADJUVANT CHEMOTHERAPY FOLLOWED BY SURGERY VERSUS SURGERY ALONE FOR PATIENTS WITH HIGH RISK RETROPERITONEAL SARCOMA

01-06-2023

-

31-05-2028

Show more information

Organisation SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG

COMED | Pushing the boundaries of Cost and Outcome analysis of Medical Technologies

01-01-2018

-

30-06-2021

Show more information

Organisation SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG

DE-ESCALATE | INTERMITTENT ANDROGEN DEPRIVATION THERAPY IN THE ERA OF ANDROGEN RECEPTOR PATHWAY INHIBITORS; A PHASE 3 PRAGMATIC RANDOMISED TRIAL

01-06-2023

-

31-05-2028

Show more information

Organisation SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG

LEGATO | Lomustine with or without reirradiation for first progression of glioblastoma: a pragmatic randomized phase III study

01-06-2023

-

31-05-2028

Show more information

Organisation SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG

Projects overview

Selected filters:

VITAL | Vaccines and Infectious Diseases in the Ageing PopuLation

Thera4Care | THERANOSTICS ECOSYSTEM FOR PERSONALISED CARE

REMEDI4ALL | BUILDING A SUSTAINABLE EUROPEAN INNOVATION PLATFORM TO ENHANCE THE REPURPOSING OF MEDICINES FOR ALL

CATALYSE | Catalysing scientific innovation into food safety action

Invest4Health | Mobilising novel finance models for health promotion and disease prevention

HTx | Next Generation Health Technology Assessment to support patient-centred, societally oriented, real-time decision-making on access and reimbursement for health technologies throughout Europe

SUSTAIN-HTA | Support Utilisation of Sustainable and TAilored INnovative methods for HTA

FoodDataQuest | On a Quest for Data-Driven Innovations to fuel Sustainable Food Systems

TRUSTING | A TRUSTworthy speech-based AI monitorING system for the prediction of relapse in individuals with schizophrenia

SELFIE | Sustainable intEgrated care modeLs for multi-morbidity: delivery, FInancing and performancE

IMMUTOL | ADVANCED ANTIGEN-SPECIFIC DENDRITIC CELL-BASED THERAPY TO RE-ESTABLISH TOLERANCE IN IMMUNE-MEDIATED DISEASES

EU-TOPIA-EAST | TOwards imProved screening for breast, cervical and colorectal cancer in Eastern-Europe: Equitable, Actionable, Sustainable and Trustworthy

HEcoPerMed | Healthcare- and pharma-economic models in support of the International Consortium for Personalised Medicine

EU-TOPIA | EU-TOPIA: TOWARDS IMPROVED SCREENING FOR BREAST, CERVICAL AND COLORECTAL CANCER IN ALL OF EUROPE

STREXIT2 | A PRAGMATIC CLINICAL STUDY OF NEOADJUVANT CHEMOTHERAPY FOLLOWED BY SURGERY VERSUS SURGERY ALONE FOR PATIENTS WITH HIGH RISK RETROPERITONEAL SARCOMA

COMED | Pushing the boundaries of Cost and Outcome analysis of Medical Technologies

DE-ESCALATE | INTERMITTENT ANDROGEN DEPRIVATION THERAPY IN THE ERA OF ANDROGEN RECEPTOR PATHWAY INHIBITORS; A PHASE 3 PRAGMATIC RANDOMISED TRIAL

LEGATO | Lomustine with or without reirradiation for first progression of glioblastoma: a pragmatic randomized phase III study